LabFirst Peptides score history

Score over time

Every entry newest first

1. October 24, 2026Lowered from7.77→to7.73(-0.04)

   Pricing recomputed on 24 October 2026 after Bionova Peptides' first-review prices were recorded; other vendors move only through the market medians: pricing 6.6 to 6.3.

2. October 24, 2026Raised from7.55→to7.77(+0.22)

   Thymosin Alpha-1 re-checked on 24 October 2026. Kovera Labs' own record for the lot now on sale, LF-65B-2609, reports a pass on every test, so the product is scored on that certificate. The failed result Kovera recorded for an earlier lot, LF-65A-2609, stays on record in the product's note. Lab 8.5 to 8.9.

3. October 23, 2026Lowered from7.57→to7.55(-0.02)

   Pricing recomputed on 23 October 2026 under the revised rule E1 (standing offers), which prices a size at the lowest total a buyer can pay without a code under standing prices, so a standing offer that includes a second vial at no extra cost now counts at all the milligrams received, in the vendor's own price and in the market medians for the same products: pricing 6.7 to 6.6.

4. October 22, 2026Raised from7.37→to7.57(+0.20)

   Re-scored on 22 October 2026 under the published rulebook, which now gives one rule for each judgement call and applies it to every vendor: shipping and refunds 6.5 to 7.5.

5. October 22, 2026Lowered from7.48→to7.37(-0.11)

   Re-scored on 22 October 2026 under version 2 of our published rules. Kovera's own record for a Thymosin Alpha-1 lot the vendor presents as passing (LF-65A-2609) reports a FAIL, so the product now scores 0 instead of carrying a separate deduction. Lab 8.7 to 8.5. Score 7.48 to 7.37.

6. October 22, 2026Lowered from8.04→to7.48(-0.56)

   Re-scored on 22 October 2026 under our published rubric for shipping, pricing, operating history and transparency, applied to every vendor the same day: prices re-read from the vendor's site and matched by milligrams per vial, operating history from the earliest dated evidence of the business, and policies scored item by item. shipping and refunds 8.0 to 6.5, pricing 8.0 to 6.7, operating history 1.0 to 0.7, transparency 8.0 to 7.0. Note added 22 October 2026: a score on this entry was corrected from 7.47 to 7.48; it had been rounded down instead of half up.

7. October 22, 2026Raised from7.54→to8.04(+0.50)

   Lab score recalculated on 22 October 2026 under the uniform published rubric applied to every vendor: earlier judgement deductions that are not part of the published rubric were removed; fixed deductions apply for posted certificate copies that differ from the laboratory's own copy. Lab 7.8 to 8.7. Note added 22 October 2026: later that day this deduction was replaced by rule A4, under which such a certificate scores 0.

8. October 16, 2026Re-checked, no change (7.54)

   No score change. A Thymosin Alpha-1 5 mg lot that was awaiting the laboratory's release at our 14 October audit was later reported by Kovera Labs as not passing, while the copy on the vendor's site had shown passing values. The vendor removed that certificate and withdrew the 5 mg size from sale within two days, and asked the laboratory to re-test the lot. The other 44 certificates match the laboratory's records.

9. October 14, 2026First publishedat7.54

   lab 7.8 / shipping 8.0 / pricing 8.0 / tenure 1.0 / transparency 8.0. Scored 7.23 on 2026-09-30 and held at the vendor's request for a second batch; the second batch added endotoxin and rapid sterility screening on 24 lots, which raised the lab score from 7.0 to 7.8.